Kidney Failure News and Research

RSS

Gilbert Hospital to provide renal dialysis services

There is a growing need for renal care, specifically, dialysis and proportionally, that growth is right here in the Valley" said David Wanger, the hospital's chief executive officer.

6 Oct 2009

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration.

From CSL Ltd 5 Oct 2009

Research study suggests possibility of safely expanding donor kidney pool by 10 to 15 percent

Kidneys recovered from deceased donors with acute renal failure (ARF) - once deemed unusable for transplant - appear to work just as well as kidneys transplanted from deceased donors who do not develop kidney problems prior to organ donation, according to a new study by researchers at Wake Forest University Baptist Medical Center.

3 Oct 2009

American Kidney Fund to host national gala to support kidney care community

In celebration of people who are living with kidney disease, as well as the individuals and corporations who are working to improve the lives of kidney patients, the American Kidney Fund will host its first national gala, The Hope Affair, at the Newseum on October 6.

3 Oct 2009

Study sheds light on why some hospitals have lower mortality than others

A compelling University of Michigan Health System study debunks assumptions about the role of complications in distinguishing good and bad hospitals.

1 Oct 2009

Altered state physiology drug development platform to treat an array of human conditions

David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

1 Oct 2009

Minimally invasive mitral valve surgery is safe and effective

Surgical treatment for mitral valve disease includes either repairing the patient's diseased valve or replacing it with a metal, mechanical valve or an animal tissue valve. The majority of those procedures are open-heart operations that require a major incision in the chest. Now, after a six-year study, surgeons at the University of Maryland Medical Center in Baltimore conclude that minimally invasive mitral valve repair techniques, through only a two-inch incision in the right side of the chest, are safe, durable and effective. The results are published in the September 2009 Annals of Surgery.

29 Sep 2009

Dialysis patients often not told about transplant options, Newspaper finds

"Thousands of kidney patients in the United States start dialysis without first being told of kidney transplants that would be cheaper and lead to longer lives, according to a four-month newspaper investigation published Sunday," The Associated Press reports.

28 Sep 2009

NIH, NephCure Foundation and University of Michigan support study of nephrotic syndrome

University of Michigan Health System researchers will lead a $10.25 million effort to study rare kidney diseases that cause kidney failure and the need for dialysis.

23 Sep 2009

Texas attemps to offer access to quality dialysis care

Local officials, physicians and patients in need of local dialysis care expressed encouragement over what appears to be a thawing of a certification logjam of dialysis facilities across the state of Texas, though remain concerned over 38 which still remain idling to many for more than a year – to the detriment of local jobs and patients in dire need of better access to quality dialysis care.

18 Sep 2009

Researchers to focus on abnormal fetal growth and chronic kidney disease

The National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University two grants totaling $3.5 million to study epigenetic changes - chemical modifications of genes caused by stress, diet or other environmental influences - and how they contribute to human diseases and biological processes.

18 Sep 2009

FDA approves Valturna tablets for treating high blood pressure

The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

18 Sep 2009

New critical illness plan from Colonial Life introduced

A new critical illness plan from Colonial Life & Accident Insurance Company can help many working Americans who may be one serious medical issue away from financial problems. Even with good health insurance, a serious illness, such as a heart attack or stroke, could leave employees on the hook for huge expenses.

15 Sep 2009

DaVita Kidney Awareness Run/Walks increases CKD awareness

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), kicks off the DaVita Kidney Awareness Run/Walks(TM) - a 10-city series of 5K events raising funds and awareness of CKD across the nation -- on Sept. 13 at Stapleton Central Park in Denver.

14 Sep 2009

End stage renal disease can be delayed by early identification of CKD

Early identification of individuals with chronic kidney disease (CKD) can delay the onset of end stage renal disease (ESRD) and the need for chronic dialysis treatments. The incidence of CKD continues to grow, and early identification and intervention are critical to manage this costly disease.

11 Sep 2009

Phase II human clinical trial of Exsulin commences

Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.

10 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

New form of malarial infection identified

Researchers in Malaysia have identified key laboratory and clinical features of an emerging new form of malaria infection. The research, funded by the Wellcome Trust, confirms the potentially deadly nature of the disease.

10 Sep 2009

Medicare advantage rates could go up, while Part D 'exceeding expectations'

"Despite near-zero inflation and recessionary conditions, health insurers in 2010 face another year of double-digit increases in the charges they pay for hospital services, physicians, drugs, and other healthcare costs," U.S. News and World Report writes in a news column.

4 Sep 2009

Reliable and relevant information needed to rein in the costs of federal health-care programs, says study

For economists and policy-makers to understand the true value of the costs and savings of preventive health programs for chronic disease, the Congressional Budget Office (CBO) should incorporate long-term clinical outcomes data and look beyond the 10-year window when making cost estimates, says a team of University of Chicago researchers in today's issue of Health Affairs.

3 Sep 2009